For IBD, No Cardiovascular Risk Difference Between JAK, TNF Inhibitors

(MedPage Today) -- ORLANDO--Major cardiovascular event risk in patients with inflammatory bowel disease (IBD) was no greater with Janus kinase (JAK) inhibitors than with tumor necrosis factor (TNF) inhibitors, according to a retrospective single...